One element of this effort will be donations made to eight food banks with the size and infrastructure to impact a significant number of Midwest neighbors in need.
The Food and Drug Administration has designated Celltrion’s Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) as interchangeable biosimilars to Prolia and Xgeva, respectively, for all approved ...
The transaction is expected to close in the second half of 2026, subject to shareholder approvals and regulatory approvals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback